Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 47(Granted Patents)

Location History:

Miyazaki, JP (1994)
Miyazaki-ken, JP (1999)
Fukuoka, JP (2017)
Toyonaka, JP (2008 - 2018)
Kurume, JP (2011 - 2021)

Company Filing History:

National Cerebral and Cardiovascular Center

patents

6. 1 out of 1,178

Takeda Pharmaceutical Company Limited

patents

7. 5 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12108746 - Transgenic animal having CREBBP gene into which mutation has been introduced (2024-10-08),

2. 11154592 - Method of treating Rett Syndrome (RTT) with ghrelin (2021-10-26),

3. 9938332 - Modified ghrelin peptides (2018-04-10),

4. 9573986 - Modified ghrelin peptides (2017-02-21),

5. 8524871 - Modified gherlin peptides (2013-09-03),

6. 8227570 - Modified gherlin peptides (2012-07-24),

7. 7943580 - Polypeptide and the use thereof (2011-05-17),

8. 7385026 - Modified ghrelin polypeptides (2008-06-10),

9. 5973134 - Rat CNP complementary DNA and precursor protein (1999-10-26),

10. 5360727 - C-terminal .alpha.-amidating enzyme and process for production thereof (1994-11-01),

Title: Masayasu Kojima: Innovator in Genetic Research

Introduction

Masayasu Kojima is a prominent inventor based in Toyonaka, Japan. He has made significant contributions to the field of genetic research, holding a total of 10 patents. His work primarily focuses on transgenic animals and methods for treating genetic disorders.

Latest Patents

Kojima's latest patents include a groundbreaking invention involving a transgenic animal that has had a mutation introduced into its CREBBP gene. This non-human transgenic animal possesses at least one CREBBP gene locus with a mutation that encodes a mutant CREBBP, which has an amino acid sequence exhibiting at least 90% identity with a specified sequence. This invention also outlines a method for producing such transgenic animals, which can serve as models for studying Rubinstein-Taybi syndrome and advanced sleep phase syndrome. Additionally, he has developed a method for treating Rett Syndrome (RTT) through the administration of ghrelin to affected subjects.

Career Highlights

Throughout his career, Kojima has worked with various institutions, including Kurume University. His research has significantly advanced the understanding of genetic disorders and potential treatments.

Collaborations

Kojima has collaborated with notable colleagues such as Hisayuki Matsuo and Kenji Kangawa, contributing to the advancement of genetic research.

Conclusion

Masayasu Kojima's innovative work in genetic research and his numerous patents highlight his dedication to improving the understanding and treatment of genetic disorders. His contributions continue to impact the field significantly.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.